1. Survival analysis of transplant-eligible newly-diagnosed multiple myeloma patients harboring t(4;14), t(14;16), and/or del(17p) in the real-world setting
- Author
-
David Garrido, Irma Slavutsky, Eloisa Riva, Camila Peña, Natalia Schutz, Luz Tarín-Arzaga, Humberto Martínez-Cordero, Virginia Bove, Rocío Osorio, Mauricio Chandía, Cecilia Beltrán, Javier Schulz, Daniela Cardemil, Carolina Contreras, Carmen Gloria Vergara, Javiera Donoso, Marcela Espinoza, Gabriel La Rocca, Hernán López-Vidal, Pilar León, Christine Rojas Hopkins, Pablo Soto, Sandra Aranda, Vivianne Torres, Macarena Roa, Paola Ochoa, Patricio Jose Duarte, Guillermina Remaggi, Sebastián Yantorno, Ariel Corzo, Soledad Zabaljauregui, Claudia Shanley, Sergio Lopresti, Sergio Orlando, Verónica Verri, Luis Quiroga, Carlos García, Vanesa Fernández, Jhoanna Ramirez, Azucena Verduga, Alicia Molina, María Pacheco, William Mantilla, Alex Mite, Inés Reyes, Brenner Sabando, Francisca Ramírez, Claudia Sossa, Virginia Abello, Henry Idrobo, Kenny Mauricio Galvez Cardenas, Domingo Saavedra, Guillermo Quintero, Raimundo Gazitúa, Lina Gaviria, Rigoberto Gomez, Mónica Osuna, Alicia Henao-Uribe, Omar Cantú-Martínez, David Gómez-Almaguer, Yarely Itzayana García-Navarrete, Antonio Cruz-Mora, Yahveth Cantero-Fortiz, Guillermo J Ruiz-Argüelles, and Dorotea Fantl
- Subjects
Cancer Research ,Oncology - Abstract
Cytogenetic abnormalities (CA) such as t(4;14), t(14;16), and del(17p), are associated with a poor prognosis in Multiple Myeloma (MM) patients. However, there is scarce information regarding the Latin-American population. This study aims to analyze the impact of t(4;14), t(14;16), and del(17p) on the progression-free survival (PFS) and overall survival (OS) of transplant-eligible newly-diagnosed MM (NDMM) patients in Latin America. Retrospective survival analysis based on the Grupo de Estudio Latinoamericano de MM (GELAMM) registry, including all adult patients with NDMM harboring CA t(4;14), t(14;16), and/or del(17p). Fifty-nine patients were included; the median age was 57 years, 55.9% males, 22% ISS-I, 25.4% ISS-II, and 47.5% ISS-III. The majority (89.8%) had 1 alteration, whereas 10.2% had del(17p) and t(4;14). The frequencies of CA were del(17p) in 61.0%, t(4;14) in 25.4%, and t(14;16) in 3,4%. Autologous stem cell transplantation (ASCT) was performed in 61.0% of cases. Five-year OS for the entire cohort was 60.8% and 5-year PFS was 28.1%. Bortezomib-based induction regimen (BBR) (P = 0.029), consolidation with ASCT (P0.001), and maintenance therapy (P = 0.004) were associated with an improved 5-year OS. In the multivariate analysis, ASCT was the only variable with a positive impact on OS (HR 0.11, 95% CI 0.033 to 0.34, P0.001). The median PFS presented a non-statistically significant benefit in BBR, ASCT, and maintenance therapy groups. BBR induction, ASCT, and maintenance therapy were associated with improved OS in high-risk NDMM patients.
- Published
- 2022